MARKSANS PHARMA
|
The Current P/E Ratio of MARKSANS PHARMA is 21.70.
| Share Price | ₹169.1 | Jan 20,2026 |
| Market Cap | ₹7,661.3 Cr | |
| Earnings-TTM | ₹353.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 21.70x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MARKSANS PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹7,661.3 Cr] as on Jan 20,2026
(/) Earnings [ ₹353.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 21.70x ]
Thus, for MARKSANS PHARMA , the investors are currently willing to pay 21.70 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MARKSANS PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MARKSANS PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MARKSANS PHARMA
PE Ratio Performance Analysis for MARKSANS PHARMA
- MARKSANS PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 15.83x.
- MARKSANS PHARMA 's operated at median p/e ratio of 11.99x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MARKSANS PHARMA 's p/e ratio peaked in Mar2025 at 26.48x.
- MARKSANS PHARMA 's p/e ratio hit its five-year low in Mar2021 of 8.67x.
How does MARKSANS PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MARKSANS PHARMA | 353.13 | 21.70 | 7,661.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 36.77 | 386,773.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 64.20 | 159,540.0 |
| CIPLA LTD | 5,453.86 | 20.41 | 111,299.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 62.86 | 134,529.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 17.02 | 97,393.0 |
| MANKIND PHARMA LTD | 1,767.06 | 49.62 | 87,675.7 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 17.66 | 87,839.2 |
| LUPIN LTD | 4,347.53 | 22.76 | 98,947.2 |
| AUROBINDO PHARMA LTD | 3,447.75 | 19.21 | 66,228.8 |
| ABBOTT INDIA LTD | 1,508.95 | 38.33 | 57,831.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MARKSANS PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.02x |
| Max industry PE | 64.20x |
| Median industry PE | 22.76x |
| Average industry PE | 33.69x |
You may also like the below Video Courses